Service d'oncologie médicale

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


972 publications

... | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 |
2016
The SIB Swiss Institute of Bioinformatics' resources: focus on curated databases.
SIB Swiss Institute of Bioinformatics Members, Bultet L.A., 2016/01/04. Nucleic acids research, 44 (D1) pp. D27-37. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_71EF45D9A3D9]
Advanced gastric cancer: Current treatment landscape and future perspectives.
Digklia A., Wagner A.D., 2016. World Journal of Gastroenterology, 22 (8) pp. 2403-2414. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9CE953713724]
 
Apnea-like suppression of respiratory motion: First evaluation in radiotherapy.
Péguret N., Ozsahin M., Zeverino M., Belmondo B., Durham A.D., Lovis A., Simons J., Long O., Duclos F., Prior J. et al., 2016. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology, 118 (2) pp. 220-226. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_721A2FE5C894]
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
Tabernero J., Vyas M., Giuliani R., Arnold D., Cardoso F., Casali P.G., Cervantes A., Eggermont A.M., Eniu A., Jassem J. et al., 2016. ESMO open, 1 (6) pp. e000142. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_765C8EC0B78B]
 
Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma?
De Bari B., Ozsahin M., Bize P., Boussaha T., Deplanque G., Wagner D., Bourhis J., Denys A., 2016. Journal of Clinical Oncology, 34 (23) pp. 2798-2799. Peer-reviewed.
[DOI][Pmid][serval:BIB_3348C7FA293C]
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Morgan G., Lambertini M., Kourie H.R., Amaral T., Argiles G., Banerjee S., Cardone C., Corral J., De Mattos-Arruda L., Öztürk A. et al., 2016. ESMO open, 1 (6) pp. e000107. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_88F99C427B52]
Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event.
Maritaz C., Metz C., Baba-Hamed N., Jardin-Szucs M., Deplanque G., 2016. Bmc Cancer, 16 (1) p. 384. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B68AD93A8657]
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.
Homulle H.A., Powolny F., Stegehuis P.L., Dijkstra J., Li D.U., Homicsko K., Rimoldi D., Muehlethaler K., Prior J.O., Sinisi R. et al., 2016. Biomedical Optics Express, 7 (5) pp. 1797-1814. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CD09E0FEA550]
 
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
Golay J., Choblet S., Iwaszkiewicz J., Cérutti P., Ozil A., Loisel S., Pugnière M., Ubiali G., Zoete V., Michielin O. et al., 2016. Journal of Immunology, 196 (7) pp. 3199-3211. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8FAA948539F4]
 
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Bonilla X., Parmentier L., King B., Bezrukov F., Kaya G., Zoete V., Seplyarskiy V.B., Sharpe H.J., McKee T., Letourneau A. et al., 2016. Nature Genetics, 48 (4) pp. 398-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8EDEF7DDCC06]
 
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M., Delic M., Goepfert K., Aust D., Grabsch H.I., Halama N., Heinrich B., Julie C., Lordick F., Lutz M.P. et al., 2016. European Journal of Cancer, 59 pp. 160-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8719495746AA]
Multilevel severe radiculopathy from an extraneural glioblastoma cervical metastasis.
Starnoni D., Yamgoué Y., Hottinger A., Bartanusz V., 2016. Surgical neurology international, 7 (Suppl 40) pp. S1028-S1029. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F6D8877E1A97]
 
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N., Biffi R., Maibach R., Hayoz S., Thierstein S., Brauchli P., Bernhard J., Stupp R., Andreoni B., Renne G. et al., 2016. Annals of Oncology, 27 (4) pp. 668-673. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_192D128068A3]
 
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Bridgewater J., Lopes A., Wasan H., Malka D., Jensen L., Okusaka T., Knox J., Wagner D., Cunningham D., Shannon J. et al., 2016. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 27 (1) pp. 134-140. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B970CA4821B1]
Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.
Herrera F.G., Berthold D.R., 2016. Frontiers In Oncology, 6 p. 117. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B2C625B19773]
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C., Bigler M., von Moos R., Bernhard J., Matter-Walstra K., Wicki A., Zaman K., Anchisi S., Küng M., Na K.J. et al., 2016. Bmc Cancer, 16 (1) p. 780. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_758B49604AD4]
 
Seeking New Approaches to Patients With Small Cell Lung Cancer
Pietanza Marie Catherine, Zimmermann Stefan, Peters Solange, Curran Walter J., 2016. pp. e477-e482 dans American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO).
[DOI][Pmid][serval:BIB_85C3502DCC98]
 
Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy.
Abdelnour-Berchtold E., Perentes J.Y., Ris H.B., Beigelman C., Lovis A., Peters S., Krueger T., Gonzalez M., 2016. World Journal of Surgery, 40 (2) pp. 373-379. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_32C436E11434]
 
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.
Peters S., Bexelius C., Munk V., Leighl N., 2016. Cancer Treatment Reviews, 45 pp. 139-162. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6759CCF2037]
 
The role of renal biopsy in small renal masses.
Burruni R., Lhermitte B., Cerantola Y., Tawadros T., Meuwly J.Y., Berthold D., Jichlinski P., Valerio M., 2016. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 10 (1-2) pp. E28-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E17D73E719CC]
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Dummer R., Siano M., Hunger R.E., Lindenblatt N., Braun R., Michielin O., Mihic-Probst D., von Moos R., Najafi Y., Guckenberger M. et al., 2016. Swiss Medical Weekly, 146 pp. w14279. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1C551DDBD145]
2015
 
The consensus molecular subtypes of colorectal cancer.
Guinney J., Dienstmann R., Wang X., de Reyniès A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P. et al., 2015/11. Nature medicine, 21 (11) pp. 1350-1356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84C36AD6D137]
 
Ist die Verordnung einer Therapie von 150 000 CHF vertretbar? [Is prescription of a therapy costing 150,000 CHF reasonable?]
Peters S., von Moos R., Thurlimann B., 2015/10/21. Revue medicale suisse, 11 (491) pp. 1967-1972. Peer-reviewed.
[Pmid][serval:BIB_60F85D761ED2]
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Baas P., Fennell D., Kerr K.M., Van Schil P.E., Haas R.L., Peters S., ESMO Guidelines Committee, 2015/09. Annals of oncology : official journal of the European Society for Medical Oncology, 26 Suppl 5 pp. v31-9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_14841043F6CC]
 
The ESMO guideline strategy: an identity statement and reflections on improvement.
Pentheroudakis G., Cardoso F., Arnold D., Sessa C., Peters S., Horwich A., Pavlidis N., Stahel R., Cervantes A., ESMO Guidelines Committee, 2015/09. Annals of oncology, 26 Suppl 5 pp. v1-7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9A1D8CB407E2]
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Girard N., Ruffini E., Marx A., Faivre-Finn C., Peters S., ESMO Guidelines Committee, 2015/09. Annals of oncology, 26 (Suppl 5) pp. v40-55. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A64670101DB8]
 
Eribulin for heavily pre-treated metastatic breast cancer patients.
Digklia A., Voutsadakis I.A., 2015/08/20. World journal of experimental medicine, 5 (3) pp. 194-199. Peer-reviewed.
[DOI][Pmid][serval:BIB_12396576EA72]
 
Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no 'sweetheart' solution.
Tabernero J., ESMO Executive Board, 2015/08. Annals of oncology, 26 (8) pp. 1529-1531. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_35EBC74D9538]
 
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
Tosi D., Laghzali Y., Vinches M., Alexandre M., Homicsko K., Fasolo A., Del Conte G., Durigova A., Hayaoui N., Gourgou S. et al., 2015/07/01. Journal of clinical oncology, 33 (19) pp. 2158-2165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_558C476141B9]
 
P-118 * Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
Faivre S. (eds.), 2015/06/01., 26 suppl 4 1, Oxford University Press (OUP).
[DOI][serval:BIB_31418E468CFF]
 
Carcinome hépatocellulaire avancé: importance des essais thérapeutiques [Advanced hepatocellular carcinoma: importance of clinical trials]
Aedo V., Cristina V., Raymond E., Faivre S., 2015/05/20. Revue medicale suisse, 11 (475) pp. 1149-1151. Peer-reviewed.
[Pmid][serval:BIB_7B026B899673]
 
Cancer testiculaire: un modèle pour optimiser le suivi radiologique [Testicular cancer: a model to optimize the radiological follow-up].
Stebler V., Pauchard B., Schmidt S., Valerio M., De Bari B., Berthold D., 2015/05. Revue Médicale Suisse, 11 (475) pp. 1144-1148.
[Pmid][serval:BIB_1E2A61B344CE]
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Eberhardt W.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S. et al., 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 26 (8) pp. 1573-1588. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFBB910B02B7]
 
Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Rolfo O, Gil-Bazo I, Peters S, 2015. European Oncology & Haematology, 2015;11(2):94–9. pp. 94-99.
[serval:BIB_46D138D98F4A]
 
An image case report of a complex pirfenidone skin rash in a patient with idiopathic pulmonary fibrosis
Sarivalasis Apostolos, Papaefthymiou Olga, Egger Bernard, 2015. International Journal of Case Reports and Images, 6 (12) p. 758.
[DOI][serval:BIB_2B0D44157FA3]
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J., Cheng P.F., Schindler K., Weide B., Held U., Frauchiger A.L., Romano E., Kähler K.C., Rozati S., Rechsteiner M. et al., 2015. Plos One, 10 (10) pp. e0139438. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_468AE65C280D]
 
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O., Mach N., Rothschild S.I., Li Q., Stahel R.A., Zippelius A., Cathomas R., Früh M., Betticher D.C., Peters S. et al., 2015. Clinical Lung Cancer, 16 (5) pp. 358-365. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3E5D55F50AAE]
 
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T., Bouchaab H., Adjei A.A., Peters S., 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer, 10 (10) pp. 1396-1403. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_110A91BCCD8A]
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O. et al., 2015. British Journal of Cancer, 113 (5) pp. 716-721. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_917B8A7CB530]
 
Cerebriforms cells in cerebrum: an unusual finding
Sarro R., Gaide O., Letourneau A., Missiaglia E., Bisig B., Hottinger A., Cairoli A., de Leval L., 2015. p. 633 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_D23B3416D5B0]
 
Clinical utility of a molecular test in adjuvant treatment decision making in women with endocrine-sensitive early stage breast cancer: a retrospective, single center one year experience
Stravodimou A., Silverio C., Nicoulaz AL, Wolfer A., Perey L., Delaloye JF, Zaman K., Fiche M., 2015. p. 636 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_B309378449FC]
 
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky M.D., Pal S.K., Chowdhury S., Harshman L.C., Crabb S.J., Wong Y.N., Yu E.Y., Powles T., Moshier E.L., Ladoire S. et al., 2015. Cancer, 121 (15) pp. 2586-2593.
[DOI][WoS][Pmid][serval:BIB_5411A0986DEE]
Correction: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).
Feilchenfeldt J., Varga Z., Siano M., Grabsch H.I., Held U., Schuknecht B., Trip A., Hamaguchi T., Gut P., Balague O. et al., 2015. British Journal of Cancer, 113 (12) p. 1747. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E022C267229]
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Dos Santos C., Tijeras-Raballand A., Serova M., Sebbagh S., Slimane K., Faivre S., de Gramont A., Raymond E., 2015. British Journal of Cancer, 112 (1) pp. 86-94. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F66A07ED9ED7]
 
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Zaman K., Winterhalder R., Mamot C., Hasler-Strub U., Rochlitz C., Mueller A., Berset C., Wiliders H., Perey L., Rudolf C.B. et al., 2015. European Journal of Cancer (oxford, England : 1990), 51 (10) pp. 1212-1220.
[DOI][WoS][Pmid][serval:BIB_AFF23D312358]
 
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O., Hoeller C., 2015. Cancer Treatment Reviews, 41 (8) pp. 660-670. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_11A220401834]
 
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C., Couvelard A., Tijeras-Raballand A., de Mestier L., de Gramont A., Bédossa P., Paradis V., Sauvanet A., Bachet J.B., Ruszniewski P. et al., 2015. Histopathology, 67 (5) pp. 664-676. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6127472F994C]
 
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M., Stupp R., Ris H.B., Stahel R.A., Weder W., Thierstein S., Gerard M.A., Xyrafas A., Früh M., Cathomas R. et al., 2015. Lancet, 386 (9998) pp. 1049-1056. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A9C926D89F3]
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C. et al., 2015. Cell Reports, 11 (4) pp. 564-576. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A7A9E6FDE41]
 
International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Moehler M., Baltin C.T., Ebert M., Fischbach W., Gockel I., Grenacher L., Hölscher A.H., Lordick F., Malfertheiner P., Messmann H. et al., 2015. Gastric Cancer, 18 (3) pp. 550-563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DB5317626E36]
 
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., Speiser D.E., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (19) pp. 6140-6145.
[DOI][WoS][Pmid][serval:BIB_D1CB1536043B]
 
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M., Tabatabai G., Kästner B., Felsberg J., Steinbach J.P., Wick A., Schnell O., Hau P., Herrlinger U., Sabel M.C. et al., 2015. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research, 21 (9) pp. 2057-2064. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F937117C954C]
 
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel R.A., Riesterer O., Xyrafas A., Opitz I., Beyeler M., Ochsenbein A., Früh M., Cathomas R., Nackaerts K., Peters S. et al., 2015. Lancet. Oncology, 16 (16) pp. 1651-1658. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C26272A946F7]
 
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Bonnefoi H., Jacot W., Saghatchian M., Moldovan C., Venat-Bouvet L., Zaman K., Matos E., Petit T., Bodmer A., Quenel-Tueux N. et al., 2015. Annals of Oncology, 26 (2) pp. 325-332. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A7149303AF76]
 
Nouveautés et perspectives dans la prise en charge des cancers colorectaux et gastriques avancés [News and perspectives in the treatment of advanced gastric and colorectal cancers].
Diciolla A., Cristina V., De Micheli R., Digklia A., Wagner A.D., 2015. Revue Médicale Suisse, 11 (475) pp. 1122, 1124-1122, 1126. Peer-reviewed.
[Pmid][serval:BIB_6313089CA2F4]
 
Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.
Stahel R., Bogaerts J., Ciardiello F., de Ruysscher D., Dubsky P., Ducreux M., Finn S., Laurent-Puig P., Peters S., Piccart M. et al., 2015. Cancer Treatment Reviews, 41 (2) pp. 129-135. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F4FA7C039DB]
Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study.
Favre-Bulle T., Baudat D., Darling K., Mamin R., Peters S., Cavassini M., Hugli O., 2015. Swiss Medical Weekly, 145 pp. w14206. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A4260C9F125A]
 
Perivascular epithelioid cell tumor (PEComa) of the uterus: A case report
Caseiro Silverio P., Achtari C., Stravodimou A., Fiche M., 2015. p. 625 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_B85B8DD7F2A0]
 
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.
Zimmermann S., Peters S., 2015. Cancer Metastasis Reviews, 34 (2) pp. 173-182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_144BD877A6B1]
 
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.
Valdagni R., Van Poppel H., Aitchison M., Albers P., Berthold D., Bossi A., Brausi M., Denis L., Drudge-Coates L., De Santis M. et al., 2015. Critical Reviews In Oncology/hematology, 95 (2) pp. 133-143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4372DDDB8B9B]
 
Recent developments and controversies in primary central nervous system lymphoma.
Hottinger A.F., Alentorn A., Hoang-Xuan K., 2015. Current Opinion In Oncology, 27 (6) pp. 496-501. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_62BE86F4002F]
 
Reinvention of chemotherapy: drug conjugates and nanoparticles.
Nguyen-Ngoc T., Raymond E., 2015. Current Opinion In Oncology, 27 (3) pp. 232-242. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_303295901F71]
Searching for targets for the systemic therapy of mesothelioma.
Stahel R.A., Weder W., Felley-Bosco E., Petrausch U., Curioni-Fontecedro A., Schmitt-Opitz I., Peters S., 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo, 26 (8) pp. 1649-1660. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_927822C7CC73]
 
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O., Milia J., Cabarrou B., Bluthgen M.V., Besse B., Smit E.F., Wolf J., Peters S., Früh M., Koeberle D. et al., 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer, 10 (10) pp. 1451-1457. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40DFB820173A]
Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Cohen R., Neuzillet C., Tijeras-Raballand A., Faivre S., de Gramont A., Raymond E., 2015. Oncotarget, 6 (19) pp. 16832-16847. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FE518F2703B]
 
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Wang X., Gronchi F., Bensimon M., Mercier T., Decosterd L.A., Wagnières G., Debefve E., Ris H.B., Letovanec I., Peters S. et al., 2015. Lasers In Surgery and Medicine, 47 (10) pp. 807-816. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B45D57A2CB25]
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M., De Maio E., Guiu S., Roca L., Dalenc F., Durigova A., Pinguet F., Bekhtari K., Jacot W., Pouderoux S., 2015. Bmc Cancer, 15 (1) p. 659. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_75B4A28E2617]
2014
 
Personalized Treatment of Advanced Non-small Cell Lung Cancer: EGFR Tyrosine Kinase Inhibitors as a Standard of Care
Stravodimou Athina, Peters Solange, 2014/12/05. The Journal of OncoPathology, 1 (4) pp. 63-71.
[DOI][serval:BIB_34A93A287504]
 
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status.
Digklia A., Voutsadakis I.A., 2014/11/20. World journal of experimental medicine, 4 (4) pp. 58-67. Peer-reviewed.
[DOI][Pmid][serval:BIB_F692C709E268]
 
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.
Peters S., Weder W., Dafni U., Kerr K.M., Bubendorf L., Meldgaard P., O'Byrne K.J., Wrona A., Vansteenkiste J., Felip E. et al., 2014/11. Journal of thoracic oncology, 9 (11) pp. 1675-1684. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C367F4947944]
 
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S., Zimmermann Stefan, Adjei A.A., 2014/09. Cancer treatment reviews, 40 (8) pp. 917-926. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7DD2E25A4F89]
 
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Zimmermann Stefan, Dziadziuszko R., Peters S., 2014/07. Cancer treatment reviews, 40 (6) pp. 716-722. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4DDFE5880FE]
 
La radiothérapie postopératoire a-t-etlle une place dans le cancer pulmonaire ? [Postoperative radiation therapy in lung carcinom]
Bouchaab H., Peters S., Ozsahin M., Peguret N., Gonzales M., Lovis A., 2014/05/21. Revue medicale suisse, 10 (431) pp. 1110-1113. Peer-reviewed.
[Pmid][serval:BIB_58D9608BE954]
 
Traitement des tumeurs maligne du foie par radiologie interventionnelle: techniques intra-artérielles [Interventional radiology procedures for malignancies of the liver treatment: Intraarterial procedures].
Cristina V., Pracht M., Lachenal Y., Adib S., Boubaker A., Prior J., Denys A., Wagner A.D., Bize P., 2014/05. Revue Médicale Suisse, 10 (431) pp. 1130-2, 1134-5. Peer-reviewed.
[Pmid][serval:BIB_BDFA56A665FC]
 
Targeted therapy in NSCLC driven by HER2 insertions.
Peters S., Zimmermann Stefan, 2014/04. Translational lung cancer research, 3 (2) pp. 84-88. Peer-reviewed.
[DOI][Pmid][serval:BIB_2D90386853EE]
 
Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer.
Voide C., Zimmermann Stefan, Adjei A.A., Betticher D.C., Meuli R., Prod'hom G., Giulieri S., Peters S., 2014/03. Journal of thoracic oncology, 9 (3) pp. e24-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_77173EE42F11]
 
Accuracy of sentinel lymph node dissection for melanoma staging in the presence of a collision tumour with a lymphoproliferative disease.
Gero D., Queiros da Mota V., Boubaker A., Berthod G., de Leval L., Demartines N., Matter M., 2014. Melanoma Research, 24 (4) pp. 371-376.
[DOI][WoS][Pmid][serval:BIB_1A03376A87FF]
 
Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
Misirlioglu H.C., Coskun-Breuneval M., Kucukpilakci B., Ugur V.I., Elgin Y., Demirkasimoglu T., Kara S.P., Ozgen A., Sanri E., Guney Y., 2014. Asian Pacific Journal of Cancer Prevention : Apjcp, 15 (20) pp. 8871-8876. Peer-reviewed.
[WoS][Pmid][serval:BIB_A3E772A6F92E]
 
Advances with Somatostatin Analogs in Neuroendocrine Tumors; the Promise of Radionuclides in Neuroendocrine Tumors
Neuzillet Cindy, Hentic Olivia, Raymond Eric, Ruszniewski Philippe, 2014. pp. 43-63 dans Raymond Eric, Faivre Sandrine, Ruszniewski Philippe (eds.) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract, Springer.
[DOI][serval:BIB_DFED49CF8DA5]
 
Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors
Neuzillet Cindy, Faivre Sandrine, Hammel Pascal, Dreyer Chantal, Raymond Eric, 2014. pp. 127-140 dans Raymond Eric, Faivre Sandrine, Ruszniewski Philippe (eds.) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract, Springer.
[DOI][serval:BIB_FD39D8CA455A]
 
Cancer du sein: radiothérapie et signalisation oestrogénique [Breast cancer: radiotherapy and estrogen signaling].
Bourgier C., Lemanski C., Romieu G., Ozsahin M., Azria D., 2014. Bulletin du Cancer, 101 (7-8) pp. 714-717. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E805CFB28C7C]
 
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Digklia A., Tzika E., Voutsadakis I.A., 2014. Journal of Oncology Pharmacy Practice, 20 (2) pp. 146-148. Peer-reviewed.
[DOI][Pmid][serval:BIB_EAFEDE77DFF7]
 
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Chambon M., Bron S., Pilotte L., Colau D., Van den Eynde B.J., Turcatti G., Vogel P., Zoete V. et al., 2014. European Journal of Medicinal Chemistry, 84 pp. 284-301.
[DOI][WoS][Pmid][serval:BIB_D4D31031A358]
 
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S., Bouchaab H., Zimmerman S., Bucher M., Gaide O., Letovanec I., Homicsko K., Michielin O., 2014. Melanoma Research, 24 (5) pp. 496-500.
[DOI][WoS][Pmid][serval:BIB_FB42577CAC5A]
 
Ensemble vers l'oncologie de précision [Together, towards precise oncology!].
Coukos G., Michielin O., Dietrich P., Aapro M., 2014. Revue Médicale Suisse, 10 (431) pp. 1099-1100.
[Pmid][serval:BIB_33962F68C3E6]
 
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A., Descatoire V., Kotelevets L., Kannengiesser C., Bertrand G., Theou-Anton N., Frey C., Genestie C., Raymond E., Chastre E. et al., 2014. Histology and Histopathology, 29 (11) pp. 1455-1466.
[WoS][Pmid][serval:BIB_BCAB1533B517]
Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Stockinger H., Altenhoff A.M., Arnold K., Bairoch A., Bastian F., Bergmann S., Bougueleret L., Bucher P., Delorenzi M., Lane L. et al., 2014. Nucleic Acids Research, 42 (Web Server issue) pp. W436-W441. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_28A5775B7C38]
 
High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience.
Cairoli A., Ketterer N., Barelli S., Duchosal M.A., 2014. Leukemia and Lymphoma, 55 (8) pp. 1827-1831.
[DOI][WoS][Pmid][serval:BIB_B5FB5BD9936B]
 
iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach.
Daina A., Michielin O., Zoete V., 2014. Journal of Chemical Information and Modeling, 54 (12) pp. 3284-3301.
[DOI][WoS][Pmid][serval:BIB_7C3EBBDEAC5D]
 
Inhibition of mTOR in Neuroendocrine Neoplasms of the Digestive Tract
Raymond Eric, Faivre Sandrine, Ruszniewski Philippe, 2014. pp. 115-126 dans Raymond Eric, Faivre Sandrine, Ruszniewski Philippe (eds.) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract, Springer.
[DOI][serval:BIB_D16D8A8F6E47]
 
Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?
Guiu S., Wolfer A., Jacot W., Fumoleau P., Romieu G., Bonnetain F., Fiche M., 2014. Critical Reviews in Oncology/hematology, 92 (3) pp. 235-257. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_633C8525BEAF]
 
L’oncologie «de précision»: un incontournable changement pour notre discipline, une révolution pour nos patients
Peters S., Raymond E., Coukos G., 2014/01/01. Bulletin Suisse du Cancer, 1 pp. 14-16.
[serval:BIB_31AE8ED58B6C]
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
[URN][DOI][WoS][Pmid][serval:BIB_09C5EADDDF4D]
 
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up?.
Reck M., Popat S., Reinmuth N., De Ruysscher D., Kerr K.M., Peters S., ESMO Guidelines Working Group, 2014. Annals of Oncology, 25 (Suppl 3) pp. iii27-iii39.
[DOI][WoS][Pmid][serval:BIB_F186AA87E909]
 
Médecine génomique et oncologie [Genomics medicine and oncology].
Michielin O., Coukos G., 2014. Praxis, 103 (10) pp. 591-596.
[DOI][Pmid][serval:BIB_9B0D168EBA26]
 
Niedrig-gradige Gliome im Erwachsenenalter [Low-grade gliomas in adults].
Kratzsch T., Gautschi O.P., Kuhn S.A., Hottinger A.F., Hildebrandt G., Stienen M.N., 2014. Praxis, 103 (23) pp. 1385-1396. Peer-reviewed.
[DOI][Pmid][serval:BIB_3ECFB10F1079]
 
Overcoming Resistance to Targeted Therapies: the Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment
Tijeras-Raballand Annemilaï, Neuzillet Cindy, Couvelard Anne, Serova Maria, de Gramont Armand, Hammel Pascal, Raymond Eric, Faivre Sandrine, 2014. pp. 167-180 dans Raymond Eric, Faivre Sandrine, Ruszniewski Philippe (eds.) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract, Springer.
[DOI][serval:BIB_9D3DA6C021F2]
 
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Medioni J., Deplanque G., Ferrero J.M., Maurina T., Rodier J.M., Raymond E., Allyon J., Maruani G., Houillier P., Mackenzie S. et al., 2014. Clinical Cancer Research, 20 (17) pp. 4471-4477.
[DOI][WoS][Pmid][serval:BIB_E47375BB3E89]
 
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle J.W., Faivre S., Hubner R.A., Grande E., Raymond E., 2014. Cancer Treatment Reviews, 40 (10) pp. 1230-1238.
[DOI][WoS][Pmid][serval:BIB_4A562E0C6867]
 
Preliminaries
Stahel Rolf, Peters Solange, 2014. pp. I-VI dans Successes and Limitations of Targeted Cancer Therapy, S. KARGER AG.
[DOI][serval:BIB_72813A029A22]
 
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton A.J., Ribi K., Surber C., Sun H., Hsu Schmitz S.F., Beyeler M., Dietrich D., Borner M., Winkler A., Müller A. et al., 2014. Breast (edinburgh, Scotland), 23 (3) pp. 244-249. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_90D8595437E8]
Radio(chemo)therapy in Elderly Patients with Esophageal Cancer: A Feasible Treatment with an Outcome Consistent with Younger Patients
Rochigneux P., Resbeut M., Rousseau F., Bories E., Raoul J.L., Poizat F., Moureau-Zabotto L., 2014. Frontiers In Oncology, 4 p. 100. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E882851FCEC2]
Standards of care and novel approaches in the management of glioblastoma multiforme.
Hottinger A.F., Stupp R., Homicsko K., 2014. Chinese Journal of Cancer, 33 (1) pp. 32-39. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCA412FE3838]
Statin use and peripheral blood progenitor cells mobilization in patients with multiple myeloma.
Stravodimou A., Voutsadakis I.A., 2014. Clinical and Translational Oncology, 16 (1) pp. 85-90. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_061E0A8E0299]
 
Successes and Limitations of Targeted Cancer Therapy
Peters Solange, Stahel Rolf, 2014/01/01. dans Progress in Tumor Research Vol. 41, 2014, Karger AG, Medical and Scientific Publishers.
[serval:BIB_34D5673DA34A]
 
Successes and Limitations of Targeted Cancer Therapy in Melanoma
Peters Solange, Stahel RA (eds.)Romano Emanuela, Michielin Olivier, 2014. Progress in Tumor Research, 41, S. KARGER AG.
[DOI][WoS][Pmid][serval:BIB_CBD38C70CA73]
 
Successes and limitations of targeted cancer therapy in melanoma.
Romano E., Michielin O., 2014. Progress in Tumor Research, 41 pp. 78-88. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC9F2F1C6482]
 
The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.
Choudhary V., Darwiche R., Gfeller D., Zoete V., Michielin O., Schneiter R., 2014. Journal of Lipid Research, 55 (5) pp. 883-894. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C1FA8D77E8F]
 
Thoracic Tumours: Essentials for Clinicians
ESMO Publishing Working Group ESMO (eds.)Peters S, 2014/01/01., ESMO book.
[serval:BIB_CC9AD25E27B7]
Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer.
Digklia A., Voutsadakis I.A., 2014. Obstetrics and Gynecology Science, 57 (6) pp. 457-463. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FF661047267E]
 
Traitement des tumeurs malignes du foie par radiologie interventionnelle: techniques ablatives [Interventional radiology procedures for malignancies of the liver: ablation procedures].
Cristina V., Pracht M., Lachenal Y., Denys A., Wagner A.D., Bize P., 2014. Revue Médicale Suisse, 10 (431) pp. 1123-1126.
[Pmid][serval:BIB_55B7A1C15E3B]
Unusual presentation of cerebral venous sinus thrombosis associated with contraceptive usage.
Panos G.D., Panos L.D., Digklia A., Hafezi F., Gatzioufas Z., 2014. Journal of Ophthalmic and Vision Research, 9 (2) pp. 281-284. Peer-reviewed.
[URN][Pmid][serval:BIB_F211B2B9A892]
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
Stravodimou A., Zaman K., Voutsadakis I.A., 2014. Isrn Oncology, 2014 p. 289836. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_079DAD2E48CF]
2013
 
Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer.
Zimmermann Stefan, Peters S., 2013/09. EJC supplements, 11 (2) pp. 307-309. Peer-reviewed.
[DOI][Pmid][serval:BIB_9935D0603744]
 
Marqueurs tumoraux: quelle utilité en pratique clinique? [Exemples of tumor markers and their clinical utility]
Sarivalasis A., Amram M.L., Dietrich P.Y., 2013/05/22. Revue medicale suisse, 9 (387) pp. 1102-1107. Peer-reviewed.
[Pmid][serval:BIB_0D10C7658ADC]
 
PET Imaging in Glioma: The Neuro-Oncologist's Expectations.
Hottinger A.F., Levivier M., Negretti L., Homicsko K., Stupp R., 2013/04. PET clinics, 8 (2) pp. 117-128. Peer-reviewed.
[DOI][Pmid][serval:BIB_503994F97E67]
A colorectal cancer classification system that associates cellular phenotype and responses to therapy.
Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., Ostos L.C., Lannon W.A., Grotzinger C., Del Rio M. et al., 2013. Nature Medicine, 19 (5) pp. 619-625. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A29B5E2F4014]
 
Bevacizumab in Lung Cancer: its impact & exceptional cases
Joerger Manfred, Peters Solange, Stahel Rolf, 2013/01/01. dans Athens Medical School Publications, 2013., Athens Medical School Publications, 2013..
[serval:BIB_1FBE048A8D2A]
 
Centre de la prostate: une approche multidisciplinaire pour une prise en charge globale du patient [Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer]
Tawadros T., Burruni R., Herrera F., Codeluppi C., Zurkinden C., Meuwly J.Y., Lhermitte B., Berthold D., 2013. Revue Médicale Suisse, 9 (409) pp. 2270-2, 2274.
[Pmid][serval:BIB_AA917B8978EC]
 
Essentials for oncologists on Thoracic cancers
Peters Solange, 2013/01/01., ESMO publications 2013 and 2017.
[serval:BIB_957272D5043C]
 
Immunothérapie: une nouvelle arme contre le cancer de la prostate [Immunotherapy: a therapeutic revolution against prostate cancer?].
Pracht M., Herrera F.G, Tawadros T., Berthold D., 2013. Revue Médicale Suisse, 9 (387) pp. 1070-1075. Peer-reviewed.
[Pmid][serval:BIB_872CCC33F242]
 
Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer.
Gonzalez M., Litzistorf Y., Krueger T., Popeskou S.G., Matzinger O., Ris H.B., Gronchi F., Lovis A., Peters S., 2013. Annals of Thoracic Surgery, 96 (1) pp. 247-252. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EA67B4B310DD]
 
IS4-5 * IS TRIPLET SUPERIOR TO DOUBLET CHEMOTHERAPY IN ADVANCED GASTRIC CANCER?
Wagner A. D., 2013. pp. ix15-ix16 dans Annals of Oncology.
[DOI][WoS][serval:BIB_79D5FCE0BE74]
 
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss.
Zaman K., Thuerlimann B., Aebi S., 2013. Journal of Clinical Oncology, 31 (27) pp. 3440-3441.
[DOI][WoS][Pmid][serval:BIB_732F110D295B]
 
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A., Chan T.A., Abrey L.E., Khasraw M., Reiner A.S., Kaley T.J., DeAngelis L.M., Lassman A.B., Nolan C.P., Gavrilovic I.T. et al., 2013. Neuro-oncology, 15 (2) pp. 242-250.
[DOI][WoS][Pmid][serval:BIB_EC57AA6A44F7]
Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer
Stravodimou A., Voutsadakis I.A., 2013. International Journal of Breast Cancer, 2013 p. 289563. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BCFB133ABD49]
 
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Hitz F., Fischer N., Pabst T., Caspar C., Berthod G., Eckhardt K., Berardi Vilei S., Zucca E., Mey U., Swiss Group for Clinical Cancer Research (SAKK) Bern Switzerland, 2013. Annals of Hematology, 92 (8) pp. 1033-1040.
[DOI][WoS][Pmid][serval:BIB_9EE26C5FC900]
Simultaneous renal oncocytoma and lymphoma: interest of lymphadenectomy
Orcurto A., Lhermitte B., Sermier A., Berthold D., 2013. Case Reports In Urology, 2013 p. 729108. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_982F4C32C44B]
 
Surgery in the Context of Multimodal Treatment of Non-Small Cell Lung Cancer.
Ris Hans-Beat, Matzinger Oscar, Lovis Alban, Peters Solange, 2013/01/01. dans Incisions, nœuds et réseaux, Les 100 ans Société Suisse de Chirurgie. Swiss Surgery Society Edition, 2013., Swiss Surgery Society Edition, 2013.
[serval:BIB_E9E8FA47B3B3]
 
Targeted treatments for metastatic esophageal squamous cell cancer.
Digklia A., Voutsadakis I.A., 2013. World Journal of Gastrointestinal Oncology, 5 (5) pp. 88-96. Peer-reviewed.
[DOI][Pmid][serval:BIB_0D8DC0748A82]
2012
 
Prise en charge orthopédique des métastases des os longs [Orthopaedic management of long bones metastasis]
Fleury T.R., Holzer N., Fleury M., Hoffmeyer P.J., 2012/12/19. Revue medicale suisse, 8 (367) pp. 2445-2446,2448-2451. Peer-reviewed.
[Pmid][serval:BIB_1CDC58CE5C6A]
Going beyond EGFR
Zimmermann S., Peters S., 2012/09/01. Annals of Oncology, 23 (suppl 10) pp. x197-x203.
[URN][DOI][WoS][Pmid][serval:BIB_27744B6D18C2]
 
Histo- and molecular pathology of lung cancer
Soltermann A, Peters S, Tischler V, 2012/08/13. pp. 32-44 dans Lung Cancer Therapy Annual 7, CRC Press.
[DOI][serval:BIB_2DC3C4D88EC1]
 
Acute cerebrovascular accident after Cisplatin treatment in a patient taking letrozole.
Digklia A., Voutsadakis I.A., 2012. Chemotherapy, 58 (6) pp. 435-438.
[DOI][WoS][Pmid][serval:BIB_CE4992C52F2C]
 
Hand and Foot Syndrome associated with docetaxel treatment.
Stravodimou A., Voutsadakis I.A., 2012. Acta Oncologica (stockholm, Sweden), 51 (4) pp. 554-556.
[DOI][WoS][Pmid][serval:BIB_705DF7F64F38]
 
Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome.
Perentes J., Bopp S., Krueger T., Gonzalez M., Jayet P.Y., Lovis A., Matzinger O., Ruffieux C., Ris H.B., Letovanec I. et al., 2012. Annals of Thoracic Surgery, 94 (6) pp. 1815-1822. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DDD65796959F]
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E., ESMO Guidelines Working Group, 2012. Annals of Oncology, 23 (Suppl 7) pp. vii56-vii64.
[URN][DOI][WoS][Pmid][serval:BIB_1FDB07D2386E]
Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Stravodimou A., Mazzoccoli G., Voutsadakis I.A., 2012. Ppar Research, 2012 p. 367450. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_179B9AF9D8C3]
 
Perspectives in Thoracic Oncology
Peters Solange, 2012/01/01., UNI-MED (Germany), 2012.
[serval:BIB_D620C442DC71]
PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis.
Stravodimou A., Cairoli A., Rausch T., Du Pasquier R., Michel P., 2012. Case Reports In Medicine, 2012 p. 239719.
[URN][DOI][Pmid][serval:BIB_AB92C502EDD1]
 
Side effects of medical cancer therapy – lung cancer
Peters Solange, Stahel Rolf, 2012/01/01., Springer Verlag UK, 2012.
[serval:BIB_1F7EAD6E7F16]
 
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner A.D., Thomssen C., Haerting J., Unverzagt S., 2012. Cochrane Database of Systematic Reviews, 7 pp. CD008941. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_323AA9BE4D26]
2011
 
ALK gene rearrangement: prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe : e european thoracic oncology group (FTOP) lungscape study
Peters S., Blackhall F., Kerr K.M., Kulig K., Bubendorf L., Thunnissen E., Dziadziuszko R., O'Byrne K.J., Baas P., Weder W. et al., 2011. pp. S1529-S1530 dans WCLC 2011, 14th World Conference on Lung Cancer, Journal of Thoracic Oncology.
[WoS][serval:BIB_FE7EB0832160]
 
Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
Moehler M., Schwarz S., Wagner A.D., 2011. Current Cancer Drug Targets, 11 (6) pp. 681-687. Peer-reviewed.
[WoS][Pmid][serval:BIB_14FA9D22AE4C]
 
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O., 2011. Revue Médicale Suisse, 7 (296) pp. 1126-1130.
[Pmid][serval:BIB_6A4C636AAB5B]
 
Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
Homicsko K., Berthold D.R., 2011/01. Anti-cancer drugs, 22 Suppl 1 pp. S4-8. Peer-reviewed.
[DOI][Pmid][serval:BIB_73800E4C3E9E]
 
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.
Bulliard Y., Narvaiza I., Bertero A., Peddi S., Röhrig U.F., Ortiz M., Zoete V., Castro-Díaz N., Turelli P., Telenti A. et al., 2011. Journal of Virology, 85 (4) pp. 1765-1776.
[DOI][WoS][Pmid][serval:BIB_512FB2191F5A]
2010
 
Traitements antiangiogéniques des cancers métastatiques du côlon et du rectum, du sein et du poumon: bénéfices et risques [Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks]
Wagner A.D., Zaman K., Peters S., Montemurro M., Leyvraz S., 2010. Revue Médicale Suisse, 6 (250) pp. 1070-1073. Peer-reviewed.
[Pmid][serval:BIB_BA7767808A25]
2009
 
Pregabalin in patients with primary brain tumors and seizures: a preliminary observation.
Novy J., Stupp R., Rossetti A.O., 2009/02. Clinical neurology and neurosurgery, 111 (2) pp. 171-173. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB3748B39386]
 
Transmission de l’information liée aux médicaments entre un centre hospitalier et une policlinique universitaire en Suisse : panorama et perspectives de continuité des soins
Fleury M, Guignard B, Guignard E, Bugnon Olivier, 2009. Pharmactuel, 42 (suppl. 1 (3)) pp. 164-174. Peer-reviewed.
[serval:BIB_5CD7E46DB2F0]
2008
 
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M., Carlisle R.C., Hernandez-Alcoceba R., Iggo R., Homicsko K., Fisher K.D., Halldén G., Mautner V., Shen Y., Seymour L.W., 2008/09. Human gene therapy, 19 (9) pp. 873-886. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2D8CA12E641D]
 
Traitements systémiques du cancer colorectal métastatique [Systemic treatment of metastatic colorectal cancer]
Montemurro M., Achtari L., Röth A., Halkic N., Luthi F., Ozsahin M., Denys A., Bauer J., Demartines N., Leyvraz S., 2008/05/21. Revue medicale suisse, 4 (158) pp. 1254-1257. Peer-reviewed.
[Pmid][serval:BIB_FCC1F9756723]
 
Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model
Yan H., Cheng C., Haouala A., Krueger T., Ballini J.P., Peters S., Decosterd L.A., Letovanec I., Ris H.B., Andrejevic-Blant S., 2008/01/01. Ann Thorac Surg, 85 (4) pp. 1225-32.
[serval:BIB_4B2F0A947D95]
2007
 
Sequential or Concomitant Chemotherapy and 3D Conformal Radiation Therapy With Dose-Volume Histogram Assessment in Limited Disease Small Cell Lung Cancer
Matzinger O., Ozsahin M., Khanfir K., El Hfid M., Peters S., Pachoud M., Bieri S., Mirimanoff R.O., Zouhair A., 2007/11., 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology pp. S529 dans International Journal of Radiation Oncology*Biology*Physics.
[DOI][WoS][serval:BIB_9C25BBB4829E]
 
Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women.
Konidaris S., Kouskouni E.E., Panoskaltsis T., Kreatsas G., Patsouris E.S., Sarivalassis A., Nonni A., Lazaris A.C., 2007/02. Health care for women international, 28 (2) pp. 182-191. Peer-reviewed.
[DOI][Pmid][serval:BIB_36A597A8A829]
 
Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women.
Konidaris S., Kouskouni E.E., Panoskaltsis T., Kreatsas G., Patsouris E.S., Sarivalassis A., Nonni A., Lazaris A.C., 2007/02. Health care for women international, 28 (2) pp. 182-191. Peer-reviewed.
[DOI][Pmid][serval:BIB_9F84518875FF]
2006
Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C., Homicsko K., Lukashev A.N., Pittet A.L., Iggo R.D., 2006/10/04. BMC cancer, 6 p. 236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5AA4B76AFD3A]
2005
 
RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.
Homicsko K., Lukashev A., Iggo R.D., 2005/08/01. Cancer research, 65 (15) pp. 6882-6890. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_64BEEC50B3BD]
 
Corrigendum to “Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC” [Eur J Cardiothorac Surg 27 (2005) 1092–1098]☆☆
Pezzetta Edgardo, Stupp Roger, Zouhair Abderrahim, Guillou Louis, Taffé Patrick, von Briel Christian, Krueger Thorsten, Ris Hans-Beat, 2005..
[DOI][WoS][serval:BIB_99BB9D93C90B]
2003
 
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
Homicskó K.G., Kertész I., Radnai B., Tóth B.E., Tóth G., Fülöp F., Fekete M.I., Nagy G.M., 2003/01. Neurochemistry international, 42 (1) pp. 19-26. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_062C0DB9B653]
2002
 
Physiological role of salsolinol: its hypophysiotrophic function in the regulation of pituitary prolactin secretion.
Tóth B.E., Bodnár I., Homicskó K.G., Fülöp F., Fekete M.I., Nagy G.M., 2002. Neurotoxicology and teratology, 24 (5) pp. 655-666. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B7FF6A1C2647]
2001
 
Salsolinol is a putative endogenous neuro-intermediate lobe prolactin-releasing factor.
Tóth B.E., Homicskó K., Radnai B., Maruyama W., DeMaria J.E., Vecsernyés M., Fekete M.I., Fülöp F., Naoi M., Freeman M.E. et al., 2001/12. Journal of neuroendocrinology, 13 (12) pp. 1042-1050. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_066F2BB1E36C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University